Endoscopic ultrasound-guided radiofrequency ablation is a safe and efficient treatment of symptomatic insulinomas – A single centre experience of 14 patients

#4418

Introduction: The vast majority of insulinomas are benign and less than 20 mm. Surgery is considered as standard treatment, but complications are significant. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) represents a novel and minimally invasive approach.

Aim(s): To evaluate efficacy of EUS-RFA in localised insulinomas.

Materials and methods: We prospectively included patients diagnosed with insulinoma based on symptomatic hypoglycaemia with inappropriate high levels of insulin. Lesions considered for RFA treatment were localised biopsy proven pNEN (Ki-67<10%), size < 25 mm. The procedures were performed under general anaesthesia. Patients were admitted for 24-hour after EUS-RFA. 3-6 months following EUS-RFA, efficacy was evaluated with EUS and 72-hours fasting test. 1 year after EUS-RFA, patients were re-evaluated for symptoms of hypoglycaemia. In case of incomplete response, patients were eligible for a 2nd treatment.

Conference:

Presenting Author: Andreassen M

Authors: Andreassen M, Kovacevic B, Brink L, Hansen C, Knigge U,

Keywords: Insulinoma, Benign, EUS, radiofrequency ablation,